Clinical characteristics of severe coronavirus disease 2019 patients with chronic obstructive pulmonary disease.
10.11817/j.issn.1672-7347.2022.210596
- Author:
Huaying LIANG
1
;
Rongli LU
2
;
Yi LI
2
;
Pinhua PAN
3
Author Information
1. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China. lhying1128@163.com.
2. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
3. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China. pinhuapan668@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
chronic obstructive pulmonary disease;
prognosis;
severe acute respiratory syndrome coronavirus 2;
severe coronavirus disease 19
- MeSH:
Male;
Female;
Humans;
Aged;
Middle Aged;
COVID-19/complications*;
SARS-CoV-2;
Retrospective Studies;
Critical Illness;
Pulmonary Disease, Chronic Obstructive/epidemiology*
- From:
Journal of Central South University(Medical Sciences)
2022;47(12):1695-1703
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Coronavirus disease 2019 (COVID-19) in elderly and patients with chronic respiratory diseases (COPD) had a poor prognosis. COPD is one of the most common chronic respiratory diseases. We explore the epidemiological characteristics of patients with severe COVID-19 with COPD patients in order to provide medical evidence for the prevention and treatment of severe COVID-19.
METHODS:We retrospectively analyzed the clinical baseline characteristics, treatment strategies, disease progression and prognosis of 557 severe COVID-19 patients admitted to the West Court of Union Hospital of Huazhong University of Science and Technology from January 29, 2020 to April 8, 2020.
RESULTS:A total of 465 patients with severe COVID-19 were enrolled in the study, including 248 (53.3%) males and 217 (46.7%) females. The median age of severe COVID-19 patients was 62.0 years, and 53 patients were complicated with COPD. Common symptoms at the onset included fever (78.5%), dry cough (67.1%), shortness of breath (47.3%) and fatigue (40.9%). Compared with non-COPD patients, patients with COPD had significantly lower levels of SpO2 in admission (90.0% vs 92.0%, P=0.014). In terms of laboratory examinations, patients with COPD had higher levels of C-reactive protein, interleukin-6, procalcitonin, total bilirubin, blood urea nitrogen, serum creatinine, lipoprotein (a), high-sensitivity troponin I, and D-dimer, while had lower levels of platelet counts, albumin and apolipoprotein AI. Severe COVID-19 patients with COPD had higher Sequential Organ Failure Assessment scores [3.0(2.0, 3.0) vs 2.0(2.0, 3.0), P=0.038] and CURB-65 score [1.0(1.0, 2.0) vs1.0(0.0, 1.0), P<0.001], and a higher proportion of progressing to critical illness (28.3% vs 10.0%, P<0.001) with more complications [e.g. septic shock (15.1% vs 6.1%, P=0.034)], had higher incidence rates of antibiotic therapies (90.6% vs 77.2%, P=0.025), non-invasive (11.3% vs 1.7%, P<0.001) and invasive mechanical ventilation (17.0% vs 8.3%, P=0.039), ICU admission (17.0% vs 7.5%, P=0.021) and death (15.1% vs 6.1%, P=0.016). Cox proportion hazard model was carried out, and the results showed that comorbid COPD was an independent risk factor for severe COVID-19 patients progressing to critical type, after adjusting for age and gender [adjusted hazard ratio (AHR)=2.38(1.30-4.37), P=0.005] and additionally adjusting for chronic kidney diseases, hypertension, coronary heart disease [AHR=2.63(1.45-4.77), P<0.001], or additionally adjusting for some statistically significant laboratory findings [AHR=2.10(1.13-3.89), P=0.018].
CONCLUSIONS:Severe COVID-19 patients with COPD have higher levels of disease severity, proportion of progression to critical illness and mortality rate. Individualized treatment strategies should be adopted to improve the prognosis of severe COVID-19 patients.
